184 related articles for article (PubMed ID: 31449183)
1. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
2. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
3. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
4. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Cathelin D; Placier S; Ploug M; Verpont MC; Vandermeersch S; Luque Y; Hertig A; Rondeau E; Mesnard L
J Am Soc Nephrol; 2014 Aug; 25(8):1662-8. PubMed ID: 24790179
[TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
6. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
Ma J; Zhang B; Liu S; Xie S; Yang Y; Ma J; Deng Y; Wang W; Xu L; Li R; Zhang L; Yu C; Shi W
PLoS One; 2013; 8(5):e64912. PubMed ID: 23741418
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
9. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
BMC Med; 2014 May; 12():81. PubMed ID: 24884842
[TBL] [Abstract][Full Text] [Related]
10. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Zhang B; Xie S; Shi W; Yang Y
Nephrol Dial Transplant; 2012 May; 27(5):1746-55. PubMed ID: 22076430
[TBL] [Abstract][Full Text] [Related]
11. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
[TBL] [Abstract][Full Text] [Related]
12. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
[TBL] [Abstract][Full Text] [Related]
13. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
[TBL] [Abstract][Full Text] [Related]
15. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
[TBL] [Abstract][Full Text] [Related]
16. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
Raij L; Tian R; Wong JS; He JC; Campbell KN
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
[TBL] [Abstract][Full Text] [Related]
17. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
18. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.
Shoji J; Mii A; Terasaki M; Shimizu A
Nephron; 2020; 144 Suppl 1():65-70. PubMed ID: 33260184
[TBL] [Abstract][Full Text] [Related]
19. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
Zhao Y; Liu L; Huang J; Shi S; Lv J; Liu G; Zhao M; Zhang H
PLoS One; 2015; 10(7):e0132869. PubMed ID: 26167688
[TBL] [Abstract][Full Text] [Related]
20. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors.
Rashmi P; Sigdel TK; Rychkov D; Damm I; Da Silva AA; Vincenti F; Lourenco AL; Craik CS; Reiser J; Sarwal MM
Ann Transl Med; 2023 Jun; 11(9):315. PubMed ID: 37404982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
